Guardant Health, Inc. (GH) is a Healthcare stock trading at $164.88 (as of 2026-08-25), with a market capitalization of $22.13B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Guardant Health provides liquid biopsy-based diagnostic tests and supporting software/data resources for oncology care and research. Its offerings include Guardant360 blood tests and GuardantINFORM, an in-silico platform using clinical-genomic datasets, along with additional test programs and solutions for connecting patient results with relevant clinical trials.
Understand Guardant Health, Inc.: how it makes money
Guardant Health develops liquid biopsy blood tests that detect and monitor cancer, selling them to oncology clinics, payers, and biopharma partners. Revenue splits across an oncology testing core, a newer screening line (Shield), and a small biopharma/data arm, with the company still deeply loss-making at scale.
Each test carries roughly 65 cents of gross profit, but the company spends the rest of its revenue on R&D and SG&A to fund Shield, Reveal, and LUNAR-2, so the model only flips positive when test volume grows fast enough to spread those fixed costs across a larger base.
Business quality (Weak): Growth is strong (44% YoY revenue) and gross margins are healthy at 65%, but a -38% operating margin and screening-stage R&D drag keep the business firmly in the pre-profitability zone.
Bull case
Shield gains mainstream payer access: UnitedHealth coverage and ACS guideline inclusion materially broaden Shield's eligible population, and management guides the Shield workflow to cut cost per test 15% by year-end 2026, improving unit economics on the fastest-growing line.
Revenue compounding at scale: Quarterly revenue reached $300M, up 44% year-over-year, with oncology volume growing 47% YoY, showing the core Guardant360 franchise is still in its adoption curve rather than plateauing.
Reveal opens a new therapy-monitoring stream: Management flagged Reveal as offering substantial potential in underpenetrated late-stage therapy monitoring, a use case where genomic monitoring is barely adopted today and represents a cross-sell layer on existing Guardant360 patients.
Bear case
Payer momentum stalls for the rest of 2026: Management does not expect major additional payer wins during the remainder of 2026, meaning Shield's growth in H2 will lean on existing formulary access rather than new coverage, capping near-term screening volume upside.
Cash burn outpaces operating cash flow: Operating margin sits at -38.5% and screening investments continue to weigh on cash generation even as the core business turns cash-flow positive, keeping the company dependent on external financing to fund the pipeline.
Reveal upside hinges on reimbursement call: Reveal's growth potential depends on pending reimbursement decisions, so the commercial ramp management is pitching cannot begin until payers formally approve coverage, creating a binary funding gap between today and full adoption.